ArticleJHEP reports : innovation in hepatology2025

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.

Risako Kohya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.